Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA

Hennion & Walsh Asset Management Inc. boosted its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 116.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 383,706 shares of the company’s stock after purchasing an additional 206,543 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.65% of Zevra Therapeutics worth $5,502,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in ZVRA. AIGH Capital Management LLC bought a new stake in shares of Zevra Therapeutics during the first quarter valued at approximately $11,184,000. UBS Group AG grew its stake in Zevra Therapeutics by 30.9% in the fourth quarter. UBS Group AG now owns 285,488 shares of the company’s stock worth $2,558,000 after purchasing an additional 67,392 shares in the last quarter. Retirement Planning Co of New England Inc. grew its stake in Zevra Therapeutics by 10.4% in the fourth quarter. Retirement Planning Co of New England Inc. now owns 662,976 shares of the company’s stock worth $5,940,000 after purchasing an additional 62,206 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in Zevra Therapeutics by 16.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company’s stock worth $2,207,000 after purchasing an additional 33,951 shares during the period. Finally, Simplify Asset Management Inc. increased its holdings in Zevra Therapeutics by 137.5% during the 1st quarter. Simplify Asset Management Inc. now owns 100,630 shares of the company’s stock worth $938,000 after purchasing an additional 58,265 shares during the period. 35.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ZVRA shares. Guggenheim lowered their target price on Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a report on Friday. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. HC Wainwright restated a “buy” rating and issued a $26.00 price objective on shares of Zevra Therapeutics in a report on Tuesday, June 23rd. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Thursday. Finally, Maxim Group increased their target price on shares of Zevra Therapeutics from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Nine investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $27.14.

Zevra Therapeutics News Summary

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Zevra reported quarterly EPS of $0.25 versus the $0.11 consensus estimate, while revenue reached $39.66 million, above expectations of $33.88 million. The company also posted a 42.82% net margin and positive operating cash flow. Zevra Therapeutics quarterly earnings report
• Positive Sentiment: Analysts remain bullish. Citizens raised its price target from $25 to $28 and assigned a “market outperform” rating. HC Wainwright maintained a “Buy” rating and a $26 target, while increasing its FY2026 EPS forecast to $0.57 from $0.55. Citizens price-target update
• Positive Sentiment: Regulatory and intellectual-property developments could improve MIPLYFFA’s long-term outlook. Zevra outlined a timeline for a CHMP reexamination opinion expected in the fourth quarter, while its MIPLYFFA Orange Book listing reportedly extends to 2041. Zevra CHMP and Orange Book update
• Neutral Sentiment: Guggenheim trimmed its price target to $23 from $24 but retained a “Buy” rating, leaving a target substantially above the current trading level. Guggenheim price-target update
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $0.13 from $0.17, signaling weaker near-term earnings expectations despite raising its full-year forecast.
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of ZVRA investors. Although no allegations or findings were detailed, the announcement introduces legal and reputational overhang. Pomerantz investor investigation

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA opened at $11.56 on Monday. The stock has a market capitalization of $686.43 million, a PE ratio of 12.57 and a beta of 0.91. The stock’s fifty day simple moving average is $12.32 and its two-hundred day simple moving average is $10.59. Zevra Therapeutics, Inc. has a 12-month low of $7.16 and a 12-month high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. On average, equities analysts predict that Zevra Therapeutics, Inc. will post 0.6 earnings per share for the current fiscal year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.